ETON vs HSTM: fair value comparison
Eton Pharmaceuticals, Inc. and HealthStream, Inc. · Updated 2026-10-19
ETON is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, ETON currently ranks higher by quality score.
| ETON | HSTM | |
|---|---|---|
| Verdict | Awaiting full valuation | Undervalued |
| Last price | $50.31 | $33.13 |
| 12-month range | $14.35–$64.43 | $19.88–$33.75 |
| Rank by discount to fair value | — | #31 of 108 Healthcare |
| Rank by quality score | #51 of 301 Healthcare | #52 of 301 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | B |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ETON fair value analysis · HSTM fair value analysis